Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes.
Lymphatic vasculature in solid tumors may serve as the pathway for metastatic spread of the cancer to the regional lymph nodes and to distant organs. Controversy still exists whether tumors metastasize through existing lymphatics or through newly formed vessels (lymphangiogenesis). The role of lymphangiogenesis in lymphoma spread and proliferation is not clearly established. VEGF-C is the most potent inducer of lymphangiogenesis. LYVE-1 was shown to be a specific marker for lymphatic vessels in normal and tumor tissue. The aim of the present study was the evaluation of lymph node LYVE-1-positive lymphatic sinus density (LSD) and VEGF-C expression in patients with non-Hodgkin's lymphoma (nHL) and in reactive lymph nodes. Sixty paraffin-embedded lymph nodes from newly diagnosed patients with B-cell nHL were evaluated. Twelve lymph node biopsy specimens from adult patients with reactive lymphonodulitis were used as controls. Sections of lymph nodes were stained immunohistochemically for LYVE-1 and VEGF-C. VEGF-C expression in lymph nodes of nHL patients was low and not significantly different from that in the control (p = 0.6). Moreover, VEGF-C expression did not differ significantly between aggressive and indolent lymphomas (p = 0.53). Similarly we did not find differences in LSD in aggressive nHL and in indolent nHL (p=0.49). The mean LSD in reactive lymph nodes was higher than in nHL (p = 0.03). Only in 2 out of 12 reactive lymph nodes LYVE-1-positive vessels were absent. In all groups we demonstrated a strong positive correlation between VEGF-C and LYVE-1-expression (p = 0.0001). Higher LSD in reactive lymph nodes as compared to those of nHL patients suggests that lymphoma proliferation leads to the destruction of the existing lymphatics rather than to lymphangiogenesis within lymph nodes. NHL are not associated with increased expression of VEGF-C nor increased LYVE-1-positive lymphatic sinuses density within lymph nodes.
Wróel
Tomasz
T
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University, Wrocław, Poland. wrobelt@hemat.am.wroc.pl
Mazur
Grzegorz
G
Dziegiel
Piotr
P
Jeleń
Michał
M
Szuba
Andrzej
A
Kuliczkowski
Kazimierz
K
Zabel
Maciej
M
D000328:Adult; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism* / Q000473:pathology*; D008208:Lymphatic System / Q000378:metabolism* / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000378:metabolism* / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism* / Q000473:pathology*; D021701:Sentinel Lymph Node Biopsy; D042582:Vascular Endothelial Growth Factor C / Q000096:biosynthesis*; D033921:Vesicular Transport Proteins
D006023:Glycoproteins; C119248:LYVE1 protein, human; D042582:Vascular Endothelial Growth Factor C; D033921:Vesicular Transport Proteins; D007770:L-Lactate Dehydrogenase